Full Coverage

Oncolytics Biotech announces issuance of 27th U.S. patent

news-medical.net
May 21, 2008
        
Story Timeline:  198 days

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses. "This patent provides the Company with... [read full story]                    

Add Comment
Latest article on this story:

Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent

 finanznachrichten.de May 23, 2008
First article on this story:

Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent

 prnewswire.com May 20, 2008
Selected publications with coverage of this story:
pharmaceutical-business-review.com redorbit.com news-medical.net prnewswire.com earthtimes.org tmcnet.com pharmiweb.co.uk newswire.ca finanznachrichten.de
RELATED
Found 8 documents:

Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent

finanznachrichten.de
May 23, 2008
        

CALGARY, May 23 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe the use of one or more recombinant...

Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent

newswire.ca
May 23, 2008
        

CALGARY, May 23 /CNW/ - "This patent provides the Company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada," said Mary Ann Dillahunty, Vice President of Intellectual Property for...

Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent

earthtimes.org
May 23, 2008
        

CALGARY, May 23 Oncolytics-Biotech CALGARY, May 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe...

                   

Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)

redorbit.com
May 22, 2008
        

CALGARY, May 22 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully transferred cGMP production for REOLYSIN(R) at the 40-litre batch size to SAFC Pharma(TM), a Division of Sigma-Aldrich Corporation.

The Maybach Review: Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for...

tmcnet.com
May 22, 2008
        

MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. On Thursday, May 22, 2008, we have added Oncolytics Biotech Inc. (NASDAQ: ONCY) to the list of potential prospects. ***Please visit our site to find genuine analyst reports on numerous...

                   

Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)

newswire.ca
May 22, 2008
        

CALGARY, May 22 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully transferred cGMP production for REOLYSIN(R) at the 40-litre batch size to SAFC Pharma(TM), a Division of Sigma-Aldrich Corporation. "Manufacturing at a commercial scale...

Oncolytics granted new patent

pharmaceutical-business-review.com
May 22, 2008
        

Oncolytics Biotech has received US patent for claims that cover pharmaceutical compositions which comprise various recombinant reoviruses. Mary Dillahunty, vice president of intellectual property at Oncolytics, said: "This patent provides the company with additional patent protection for reovirus...

Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent

newswire.ca
May 20, 2008
        

CALGARY, May 20 /CNW/ - "This patent provides the Company with additional patent protection for reovirus compositions in the United States," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology...